NASHVILLE, Tennessee (WKRN) – The Clinical Trials Center of Middle Tennessee has joined a new national study that is testing three drugs, including ivermectin, that could treat symptoms of COVID-19.
The CTC is now recruiting people 30 years of age or older who have tested positive for COVID-19 and are showing symptoms to participate in the trial.
The trial will include testing of drugs already approved by the Federal Drug Administration for the efficacy and safe treatment of mild to moderate symptoms of COVID-19.
Drugs reused include: ivermectin, fluticasone and fluvoxamine.
Ivermectin is primarily used to treat parasitic infections in horses. Recently, the FDA, among other officials, urged people not to use the drug to fight symptoms of COVID.
The steroid, Fluticasone, may sound familiar to those with allergies. It is currently used for allergy relief, asthma control, and chronic obstructive pulmonary disease.
And, Fluvoxamine is often prescribed for depression.
“We are very happy to participate in this important research project,” said Dr Alex J. Slandzicki. “There is currently no approved prescription drug that can be easily administered at home to treat mild to moderate COVID early in its course to prevent worsening symptoms and reduce the need for hospitalization. ”
Dr Slandzicki and Dr Aaron Milstone will be the principal investigators of the Middle Tennessee CTC in this study.
“We know the need for outpatient treatment will continue to grow as we see more cases, so this is a vital public health need,” Dr Milstone said.
The study, called ACTIV-6, is a national, double-blind study that is expected to involve 15,000 participants from across the country.
To be eligible for the study, you must be 30 years of age or older, have a positive COVID test within 10 days, and at least two COVID symptoms.
Symptoms include fatigue, difficulty breathing, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, and / or new loss of taste or smell.
If you or someone you know is interested in signing up for the trial, you can contact the CTC at (615) 205-8350 or click on this link.
Suggest a correction